NO314824B1 - Drikk og törr sammensetning - Google Patents
Drikk og törr sammensetning Download PDFInfo
- Publication number
- NO314824B1 NO314824B1 NO19961809A NO961809A NO314824B1 NO 314824 B1 NO314824 B1 NO 314824B1 NO 19961809 A NO19961809 A NO 19961809A NO 961809 A NO961809 A NO 961809A NO 314824 B1 NO314824 B1 NO 314824B1
- Authority
- NO
- Norway
- Prior art keywords
- drink
- glucose
- energy
- water
- ketoglutaric acid
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 15
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 claims abstract description 46
- HWXBTNAVRSUOJR-UHFFFAOYSA-N alpha-hydroxyglutaric acid Natural products OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229940009533 alpha-ketoglutaric acid Drugs 0.000 claims abstract description 19
- 235000013361 beverage Nutrition 0.000 claims abstract description 10
- 241000124008 Mammalia Species 0.000 claims abstract description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 31
- 239000008103 glucose Substances 0.000 claims description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 8
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 8
- 239000001630 malic acid Substances 0.000 claims description 8
- 235000011090 malic acid Nutrition 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 7
- 150000004676 glycans Chemical class 0.000 claims description 6
- 239000004615 ingredient Substances 0.000 claims description 6
- 229920001282 polysaccharide Polymers 0.000 claims description 6
- 239000005017 polysaccharide Substances 0.000 claims description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 5
- 239000011575 calcium Substances 0.000 claims description 5
- 229910052791 calcium Inorganic materials 0.000 claims description 5
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 5
- 229930195729 fatty acid Natural products 0.000 claims description 5
- 239000000194 fatty acid Substances 0.000 claims description 5
- 150000004665 fatty acids Chemical class 0.000 claims description 5
- 239000011591 potassium Substances 0.000 claims description 5
- 229910052700 potassium Inorganic materials 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 229930091371 Fructose Natural products 0.000 claims description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 4
- 239000005715 Fructose Substances 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims 1
- 235000021321 essential mineral Nutrition 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 150000003839 salts Chemical class 0.000 abstract description 4
- 210000003205 muscle Anatomy 0.000 description 25
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 12
- 238000012549 training Methods 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 238000012360 testing method Methods 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 7
- 229920002527 Glycogen Polymers 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 6
- 230000037406 food intake Effects 0.000 description 6
- 235000012631 food intake Nutrition 0.000 description 6
- 229940096919 glycogen Drugs 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 230000032258 transport Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 4
- 230000036314 physical performance Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000008934 Muscle Proteins Human genes 0.000 description 3
- 108010074084 Muscle Proteins Proteins 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 229960003624 creatine Drugs 0.000 description 3
- 239000006046 creatine Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 235000020774 essential nutrients Nutrition 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 235000011496 sports drink Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940120503 dihydroxyacetone Drugs 0.000 description 2
- 238000004146 energy storage Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000000446 fuel Substances 0.000 description 2
- 210000005095 gastrointestinal system Anatomy 0.000 description 2
- 230000004190 glucose uptake Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000031891 intestinal absorption Effects 0.000 description 2
- 230000003871 intestinal function Effects 0.000 description 2
- 150000004715 keto acids Chemical class 0.000 description 2
- 150000002605 large molecules Chemical class 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 101000950981 Bacillus subtilis (strain 168) Catabolic NAD-specific glutamate dehydrogenase RocG Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000016901 Glutamate dehydrogenase Human genes 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- -1 glucose Chemical class 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000018883 loss of balance Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 235000006286 nutrient intake Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000006180 nutrition needs Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 230000003863 physical function Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 229940071440 soy protein isolate Drugs 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000007103 stamina Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 235000021404 traditional food Nutrition 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000005068 transpiration Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/68—Acidifying substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S426/00—Food or edible material: processes, compositions, and products
- Y10S426/804—Low calorie, low sodium or hypoallergic
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S426/00—Food or edible material: processes, compositions, and products
- Y10S426/81—Energy rations, e.g. emergency rations, survival rations
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Non-Alcoholic Beverages (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Tea And Coffee (AREA)
- Manufacture Of Tobacco Products (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9303691A SE9303691D0 (sv) | 1993-11-09 | 1993-11-09 | New beverage |
PCT/SE1994/001048 WO1995012991A1 (en) | 1993-11-09 | 1994-11-08 | New beverage |
Publications (3)
Publication Number | Publication Date |
---|---|
NO961809D0 NO961809D0 (no) | 1996-05-03 |
NO961809L NO961809L (no) | 1996-06-24 |
NO314824B1 true NO314824B1 (no) | 2003-06-02 |
Family
ID=20391686
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19961809A NO314824B1 (no) | 1993-11-09 | 1996-05-03 | Drikk og törr sammensetning |
Country Status (12)
Country | Link |
---|---|
US (1) | US5817364A (fi) |
EP (1) | EP0727947B1 (fi) |
JP (1) | JPH09504945A (fi) |
CN (1) | CN1076183C (fi) |
AT (1) | ATE247909T1 (fi) |
AU (1) | AU685882B2 (fi) |
CA (1) | CA2176134A1 (fi) |
DE (1) | DE69433092D1 (fi) |
FI (1) | FI961947A (fi) |
NO (1) | NO314824B1 (fi) |
SE (1) | SE9303691D0 (fi) |
WO (1) | WO1995012991A1 (fi) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1409299A (en) * | 1997-11-13 | 1999-06-07 | University Of Florida | Use of ketoacids together with amino acids for enhancing muscle performance and recovery from fatigue |
US6514545B1 (en) | 1997-11-17 | 2003-02-04 | Robert E. Weinstein | Assemblage of nutrient beverages and regimen for enhancing convenience, instruction, and compliance with exercise supplementation |
US6013290A (en) * | 1997-11-17 | 2000-01-11 | Weinstein; Robert E. | Assemblage of nutrient beverages and regimen for enhancing convenience, instruction, and compliance with exercise supplementation |
US6214390B1 (en) | 1997-11-17 | 2001-04-10 | Robert E. Weinstein | Assemblage of nutrient beverages and regimen for enhancing convenience, instruction, and compliance with exercise supplementation |
US6221910B1 (en) | 1999-07-22 | 2001-04-24 | The University Of New Mexico | Glutamine containing oral replacement solution |
CN1457255A (zh) | 2001-02-14 | 2003-11-19 | 马蒂亚斯·拉特 | 参与细胞生物能代谢的生物化学化合物的组合物和其使用方法 |
US7740893B2 (en) * | 2001-04-02 | 2010-06-22 | Mott's Llp | Sports drink composition for enhancing glucose uptake into the muscle and extending endurance during physical exercise |
US6989171B2 (en) * | 2001-04-02 | 2006-01-24 | Pacifichealth Laboratories, Inc. | Sports drink composition for enhancing glucose uptake into the muscle and extending endurance during physical exercise |
SE0201713D0 (sv) | 2001-11-23 | 2002-06-06 | Gramineer Internat Ab | New methods and use III |
US20060247207A1 (en) * | 2003-07-01 | 2006-11-02 | Pierzynowski Stefan G | Use of alpha-ketoglutaric acid for the treatment of malnutrition or high plasma glucose condition |
SE0301947D0 (sv) * | 2003-07-01 | 2003-07-01 | Gramineer Internat Ab | New method and uses |
PL368572A1 (en) * | 2004-06-17 | 2005-12-27 | Sgp & Sons Ab | Pharmaceutical compound for prevention and therapy of increased level of cholesterol, ldl and triglycerides as well as application of the pharmaceutical compound as an agent acting against atherosclerosis and used in circulatory system affections |
US20060134300A1 (en) * | 2004-12-20 | 2006-06-22 | Newman Arnold L | Nutritional supplement for caffeine-containing beverages |
RU2454999C2 (ru) * | 2005-11-15 | 2012-07-10 | Энтресс Аб | Лекарственное средство, применяющееся при поражениях хряща |
CN101472613A (zh) * | 2006-04-12 | 2009-07-01 | R·L·亚历山大 | 包含丙酮酸烷基酯的组合物及其应用 |
PL379512A1 (pl) * | 2006-04-21 | 2007-10-29 | Sgp & Sons Ab | Nowe metody i ich zastosowanie |
US7566463B2 (en) * | 2006-05-03 | 2009-07-28 | C. B. Fleet Company | Oral rehydration compositions |
WO2009005379A1 (en) * | 2007-07-03 | 2009-01-08 | Danuta Kruszewska | New medical applications of alpha-ketoglutarate |
AU2008282445A1 (en) * | 2007-07-27 | 2009-02-05 | Gilmore Sports Ii, Llc | Exercise performance and recovery formulations |
EP2098124A1 (en) | 2008-03-03 | 2009-09-09 | Nestec S.A. | Carbohydrate gel |
US20090280229A1 (en) * | 2008-05-07 | 2009-11-12 | Constantine Wendy L | Method and apparatus for manufacturing protein beverages |
EP2177113A1 (en) * | 2008-10-15 | 2010-04-21 | Nestec S.A. | Improved liver glycocen synthesis |
DE102009016119A1 (de) * | 2009-04-03 | 2010-10-14 | Evonik Degussa Gmbh | Nahrungsergänzungsmittel enthaltend alpha-Ketosäuren zur Unterstützung der Diabetestherapie |
US20150157660A1 (en) * | 2013-12-10 | 2015-06-11 | Lifewave, Inc. | Nutritional product composition for energy |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE462463C (de) * | 1928-07-11 | Constanz Petersmann | Nachgiebige Streckenauskleidung aus Natursteinen | |
US4001448A (en) * | 1973-05-14 | 1977-01-04 | General Foods Corporation | Beverage mix and method of manufacturing same |
US4309417A (en) * | 1980-07-10 | 1982-01-05 | Stauffer Chemical Company | Protein fortified isotonic beverages |
SE8704217D0 (sv) * | 1987-10-29 | 1987-10-29 | Vinnars Erik Ab | Aminosyrakomposition for parenteral neringstillforsel |
SE462463B (sv) * | 1988-12-02 | 1990-07-02 | Decken Alexandra V D | Livs- och fodermedel innehaallande ketosyror |
DE3943424A1 (de) * | 1989-12-30 | 1991-07-04 | Nephro Medica Pharma | Infusions- und injektionsloesung zur intravenoesen verabreichung |
SE9003844L (sv) * | 1990-12-03 | 1992-06-04 | Kabi Pharmacia Ab | Naeringstillsats |
SE9201584D0 (sv) * | 1992-05-20 | 1992-05-20 | Vinnars Erik Ab | Use of alpha-ketoglutarate |
US5270297A (en) * | 1992-07-23 | 1993-12-14 | Metagenics, Inc. | Endurance and rehydration composition |
-
1993
- 1993-11-09 SE SE9303691A patent/SE9303691D0/xx unknown
-
1994
- 1994-11-08 DE DE69433092T patent/DE69433092D1/de not_active Expired - Lifetime
- 1994-11-08 AU AU10378/95A patent/AU685882B2/en not_active Ceased
- 1994-11-08 WO PCT/SE1994/001048 patent/WO1995012991A1/en active IP Right Grant
- 1994-11-08 AT AT95900974T patent/ATE247909T1/de not_active IP Right Cessation
- 1994-11-08 EP EP95900974A patent/EP0727947B1/en not_active Expired - Lifetime
- 1994-11-08 US US08/637,666 patent/US5817364A/en not_active Expired - Lifetime
- 1994-11-08 CA CA002176134A patent/CA2176134A1/en not_active Abandoned
- 1994-11-08 CN CN94194314A patent/CN1076183C/zh not_active Expired - Fee Related
- 1994-11-08 JP JP7513763A patent/JPH09504945A/ja not_active Ceased
-
1996
- 1996-05-03 NO NO19961809A patent/NO314824B1/no not_active IP Right Cessation
- 1996-05-08 FI FI961947A patent/FI961947A/fi unknown
Also Published As
Publication number | Publication date |
---|---|
AU685882B2 (en) | 1998-01-29 |
NO961809D0 (no) | 1996-05-03 |
FI961947A0 (fi) | 1996-05-08 |
ATE247909T1 (de) | 2003-09-15 |
SE9303691D0 (sv) | 1993-11-09 |
JPH09504945A (ja) | 1997-05-20 |
FI961947A (fi) | 1996-06-13 |
AU1037895A (en) | 1995-05-29 |
CN1076183C (zh) | 2001-12-19 |
WO1995012991A1 (en) | 1995-05-18 |
EP0727947B1 (en) | 2003-08-27 |
EP0727947A1 (en) | 1996-08-28 |
DE69433092D1 (de) | 2003-10-02 |
NO961809L (no) | 1996-06-24 |
CA2176134A1 (en) | 1995-05-18 |
CN1136266A (zh) | 1996-11-20 |
US5817364A (en) | 1998-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO314824B1 (no) | Drikk og törr sammensetning | |
Williams et al. | Effects of recovery beverages on glycogen restoration and endurance exercise performance | |
Walberg | Aerobic exercise and resistance weight-training during weight reduction: Implications for obese persons and athletes | |
US7993690B2 (en) | Carbohydrate and electrolyte replacement composition | |
US5292774A (en) | Substitution fluid preparation comprising 3-hydroxy-butyric acid (β-hydroxybutric acid) and its salts | |
US20030099722A1 (en) | Methods and compositions for providing glutamine | |
Sanderson et al. | Effects of dietary fat and L-carnitine on plasma and whole blood taurine concentrations and cardiac function in healthy dogs fed protein-restricted diets | |
Kim et al. | Octacosanol supplementation increases running endurance time and improves biochemical parameters after exhaustion in trained rats | |
Hultman | Nutritional effects on work performance | |
Hagobian et al. | Interactions between energy surplus and short-term exercise on glucose and insulin responses in healthy people with induced, mild insulin insensitivity | |
Brouns | Essentials of sports nutrition | |
Miller et al. | Metabolic response to provision of mixed protein-carbohydrate supplementation during endurance exercise | |
RU2619223C2 (ru) | Профилактика или лечение избыточной массы и ожирения у пациентов с диабетом 2 типа | |
Hofmann et al. | Plasma pyridoxal and pyridoxal 5′-phosphate concentrations in response to ingestion of water or glucose polymer during a 2-h run | |
US20100256058A1 (en) | Exercise performance and recovery formulations | |
van Loon et al. | 18 Dietary considerations for sport and exercise | |
CA1334575C (en) | Substitution fluid preparation comprising 3-hydroxybutyric acid (beta-hydroxybutyric acid) and its salts | |
DK164200B (da) | Praeparat til forbedring af den cellulaere metabolisme | |
Dardevet et al. | Fructose feeding during the postabsorptive state alters body composition and spares nitrogen in protein-energy-restricted old rats | |
Scalfi et al. | Protein balance during very-low-calorie diets for the treatment of severe obesity | |
Ghazzawi et al. | Exploring the Relationship between Micronutri-ents and Athletic Performance: A Comprehensive Systematic Review of the Literature in Sports Medicine. Sports 2023, 11, 109 | |
Vormann et al. | Latent acidosis: overacidification as a cause of chronic diseases | |
Okada et al. | Effect of exercise on the metabolism of vitamin B6 and some PLP-dependent enzymes in young rats fed a restricted vitamin B6 diet | |
Hofman et al. | Glucose and insulin responses after commonly used sport feedings before and after a 1-hr training session | |
Cross et al. | Nutrition for Injury Recovery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |